Last reviewed · How we verify
NCT05475288
Incidence, Risk Factor, Treatment and Overall Survival of Locoregionally Recurrent Colon Cancer
trial in Colonic Neoplasms in 3,554 participants. Completed in 30 June 2015.
30 June 2015
Quick facts
| Lead sponsor | Radboud University Medical Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,554 |
| Start date | 1 January 2015 |
| Primary completion | 30 June 2015 |
| Estimated completion | 30 June 2015 |
Conditions studied
- Colonic Neoplasms — all drugs for Colonic Neoplasms →
- Neoplasm Recurrence, Local — all drugs for Neoplasm Recurrence, Local →
Sponsor
Radboud University Medical Center
Who can join
18 and older, any sex, with Colonic Neoplasms or Neoplasm Recurrence, Local. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Data on disease recurrence was collected for all primary colon cancer patients diagnosed in the Netherlands over the first six months of 2015. Three-year cumulative incidence, risk factors, treatment and three-year OS of locoregionally recurrent colon cancer were determined.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Locoregionally Recurrent Colon Cancer: How Far Have We Come? A Population-Based, Retrospective Cohort Study.
Swartjes H, van Lankveld DWP, van Erning FN, Verheul HMW, et al · · 2023 · cited 9× · PMID 36261752 · DOI 10.1245/s10434-022-12689-5
Verify or expand the search:
- PubMed search for NCT05475288
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colonic Neoplasms
Currently open trials in the same condition.
- NCT07173985 — Strategies for Optimizing a Mailed FIT Program in Appalachia · NA · recruiting
- NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
- NCT06371898 — Comparison of MORbidity of Submucosal DIssection Resection of Giant cOlon Lesions Versus Surgery: a National Multicenter · active not recruiting
- NCT06119867 — CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE) · Phase 3 · recruiting
- NCT06124378 — Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer · Phase 2 · active not recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
- NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
- NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
- NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
- NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
- NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05475288 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
- Last refreshed: 26 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05475288.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing